
    
      This will be a prospective, single-center study. Eligible subjects will present with a
      minimum 20% Total Body Surface Area (TBSA) burn injury and expected to receive the standard
      dose of intravenous Vitamin K (10mg/day). Exclusion criteria will include any patient
      admitted with a history of, or having present at baseline: bleeding disorders,
      thrombocytopenia, coagulopathy, or liver dysfunction (MELD Score â‰¥20). Subjects who are
      moribund, or in the opinion of the investigator, not expected to survive will be excluded, as
      well as burns induced as a result of a suicide attempt.

      The study will enroll approximately 25 subjects in the prospective arm and 25 subjects will
      be matched from our medical record data base to the basic subject criteria for the chart
      review portion of the study. Study duration will be 90 days.

      The research foundation will request exemption, waiver of HIPAA (Health Insurance Portability
      and Accountability Act) authorization and waiver of informed consent for the data collection
      /cohort portion of the study as only burn injury demographics, lab results and dosing regimen
      will be collected. No protected health information (PHI) will be recorded on patients
      identified for the cohort arm of the study.
    
  